R. Kuhelj

发表

Cathepsin B/Cystatin C Complex Levels in Sera from Patients with Lung and Colorectal Cancer

H. Nielsen, N. Brünner, J. Kos, 2001, Biological chemistry.

Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort study

B. Weinstock-Guttman, E. Havrdová, H. Butzkueven, 2022, medRxiv.

Cathepsin B/Cystatin C Complex Levels in Sera from Patients with Lung and Colorectal Cancer

H. Nielsen, N. Brünner, J. Kos, 2001 .

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Autocatalytic processing of recombinant human procathepsin B is a bimolecular process

V. Turk, B. Turk, J. Stojan, 1999, FEBS letters.

Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen.

D. Turk, V. Turk, M. Podobnik, 1997, Journal of molecular biology.

Crystal structures of human procathepsin B at 3.2 and 3.3 Å resolution reveal an interaction motif between a papain‐like cysteine protease and its propeptide

D. Turk, V. Turk, M. Dolinar, 1996, FEBS letters.

Inhibition of Human Endogenous Retrovirus-K10 Protease in Cell-free and Cell-based Assays*

Chong-Hwan Chang, P. Jadhav, B. Korant, 2001, Journal of Biological Chemistry.

Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.

Jeffrey A. Cohen, D. Arnold, H. Wiendl, 2023, Multiple sclerosis and related disorders.

The preparation of catalytically active human cathepsin B from its precursor expressed in Escherichia coli in the form of inclusion bodies.

V. Turk, J. Pungerčar, M. Dolinar, 1995, European journal of biochemistry.

Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results)

P. Vermersch, G. Comi, H. Wiendl, 2019, Journal of the Neurological Sciences.

Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)

P. Vermersch, H. Wiendl, R. Nicholas, 2020 .

Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.

N. Campbell, K. Smirnakis, Jennifer Lyons, 2023, Expert opinion on drug safety.